Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04640987 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
A Phase 1 study of Hematologic Diseases, sponsored by Porteus, Matthew, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04640987 is a Phase 1 study of Hematologic Diseases that is actively recruiting participants, run by Porteus, Matthew, MD. The registered enrollment target is 22 participants, below the 2,237-participant average among 17 other Hematologic Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04640987, a Phase 1 study of Hematologic Diseases, is actively recruiting participants, sponsored by Porteus, Matthew, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD). The primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in children and young adults with hematologic malignancies. A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution. All participants on this study must be enrolled on another study: NCT04249830
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Stem Cell Transplant
- DEVICE CliniMACS Prodigy System
- DRUG T-allo10 cells addback
Study Locations (1)
California
- Lucile Packard Children's Hospital - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04640987
The ClinicalTrials.gov registry entry for NCT04640987 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,237-participant average among 17 other Hematologic Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Porteus, Matthew, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Diseases appearing as the primary indexed condition, and to 3 interventions - of which Allogeneic Stem Cell Transplant is the first listed.
NCT04640987 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04640987 about?
NCT04640987 is a clinical study titled "Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback". The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD). The primary objective of Phase 1a i...
What is the current status of trial NCT04640987?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-02-10. Estimated completion is 2029-03.
What conditions does trial NCT04640987 study?
This clinical trial studies the following conditions: Hematologic Diseases.
What interventions are being tested in trial NCT04640987?
The interventions under investigation include: Allogeneic Stem Cell Transplant (BIOLOGICAL), CliniMACS Prodigy System (DEVICE), T-allo10 cells addback (DRUG).
Who is sponsoring clinical trial NCT04640987?
This trial is sponsored by Porteus, Matthew, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04640987 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
RECRUITING
-
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.